Analyst Price Targets — BLTE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 26, 2026 9:50 am | Graig Suvannavejh | Mizuho Securities | $215.00 | $137.30 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho |
| May 22, 2026 1:33 pm | — | Truist Financial | $217.00 | $140.35 | StreetInsider | Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) |
| March 4, 2026 11:41 am | Yi Chen | H.C. Wainwright | $200.00 | $171.51 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Raised to $200 at H.C. Wainwright |
| March 3, 2026 1:18 pm | — | Needham | $217.00 | $177.50 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Raised to $217 at Benchmark Following Business Update |
| February 19, 2026 12:17 pm | Graig Suvannavejh | Mizuho Securities | $223.00 | $173.91 | TheFly | Belite Bio price target raised to $223 from $194 at Mizuho |
| January 6, 2026 10:00 am | — | Morgan Stanley | $191.00 | $159.42 | TheFly | Belite Bio initiated with an Overweight at Morgan Stanley |
| December 3, 2025 1:44 pm | — | BTIG | $187.00 | $153.70 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Raised to $187 at Benchmark on Positive Phase 3 Dragon Trial Results |
| December 2, 2025 8:05 pm | — | Maxim Group | $200.00 | $150.84 | TheFly | Belite Bio price target raised to $200 from $140 at Maxim |
| December 2, 2025 10:11 am | Graig Suvannavejh | Mizuho Securities | $194.00 | $154.02 | TheFly | Belite Bio upgraded to Outperform from Neutral at Mizuho |
| December 1, 2025 4:32 pm | — | H.C. Wainwright | $185.00 | $153.65 | TheFly | Belite Bio price target raised to $185 from $98 at H.C. Wainwright |
Latest News for BLTE
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on…
Belite Bio NASDAQ: BLTE Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy secondary to age-related macular degeneration, two severe retinal diseases with overlapping features.
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday,…
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite data will be presented at the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of…
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLTE.
U.S. House Trading
No House trades found for BLTE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.